Category - Feature

Feature

Har Grover talks up GeneTether TNT platform

As CEO of closely-held GeneTether, Har Grover is tackling the emerging potential of gene editing, which has come alive in the past few years. As an entrepreneur, investor, senior executive and strategist with over 30...

July 13, 2021

Feature

Sio Gene Therapies developing CNS-targeted gene therapies

Sio Gene Therapies (NASDAQ:SIOX) is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric...

July 6, 2021

Feature

Seelos Therapeutics addressing unmet needs in CNS disorders

Seelos Therapeutics’ (NASDAQ:SEEL) two late-stage programs are addressing significant unmet needs in CNS disorders, including acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder and...

June 29, 2021

Feature

Arctic Vision sees busy ophthalmic business development in 2021

After closing four licensing deals for five assets in 2020 and so far in 2021, including its latest deal in early June, closely-held Arctic Vision, a leading player in China’s ophthalmology market, has no plans to slow...

June 22, 2021

Feature

CymaBay laser focused on seladelpar pivotal trial for PBC

After resolving a delay in its biliary cholangitis (PBC) program, CymaBay Therapeutics (NASDAQ:CBAY) is activating clinical sites in North America and Europe, and recruiting patients in its global RESPONSE registration...

June 15, 2021

Feature

Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics

Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in order to...

June 8, 2021

Feature

Cognetivity Neurosciences tackling dementia when it counts

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF) is using artificial intelligence to enable early detection of cognitive decline in neurodegenerative disorders, such as dementia and Alzheimer’s disease, the leading...

June 1, 2021

Feature

Gregory Penner takes us into the world of aptamers

As president, a co-founder and CEO of closely-held NeoVentures Biotechnology, Gregory Penner, Ph.D., took a different route developing aptamers for healthcare solutions. His training was in quantitative genetics of crop...

May 25, 2021

Feature

Azura Ophthalmics taking dermatological approach to ocular surface diseases

Closely-held Azura Ophthalmics is developing the first ophthalmic keratolytics for the treatment of lid margin diseases, such as Meibomian gland dysfunction (MGD), blepharitis, dry eye disease and contact lens...

May 18, 2021

Feature

MiMedx’s proprietary tissue technology utilizing amniotic tissue as a platform for regenerative medicine

MiMedx Group (NASDAQ:MDXG) is forging ahead with its corporate turnaround as an industry leader in advanced wound care. “As a pioneer in amniotic tissue biologics, we have both a core business, focused on addressing the...

May 11, 2021

Category - Feature

Har Grover talks up GeneTether TNT platform

Sio Gene Therapies developing CNS-targeted gene therapies

Seelos Therapeutics addressing unmet needs in CNS disorders

Arctic Vision sees busy ophthalmic business development in 2021

CymaBay laser focused on seladelpar pivotal trial for PBC

Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics

Cognetivity Neurosciences tackling dementia when it counts

Gregory Penner takes us into the world of aptamers

Azura Ophthalmics taking dermatological approach to ocular surface diseases

MiMedx’s proprietary tissue technology utilizing amniotic tissue as a platform for regenerative medicine

General

More